Replies to post #3373 on Insmed Inc (INSM)

[Do DD]

You're now citing Geoffrey Allan, not Phil Young as stated by you earlier.

The exact paragraph from the evidence (as spoken by Allan):

We continued our label expansion studies for IPLEX and now we have ongoing clinical studies where we are evaluating the value of IPLEX in several disease areas, such as severe insulin resistance, myotonic muscular dystrophy, AIDS [unintelligible] dystrophy and we're about to initiate a new clinical study in children with Newman's Syndrome.
Positive data from our severe insular resistance study and our pivotal IGFD studies were presented at several [unintelligible] of the Congress this last quarter and we hope to present top-line data from these new studies in the first half of 2007.


However: we're nitpicking about stuff which was clarified by Phil Young during the R&R CC. I urge anyone who is interested in the status of the trials to relisten the R&R CC and form his/her own opinion.

Sincerely, E.